A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

Running, not enrolling · Phase 3

Conditions studied: Cystic Fibrosis

In brief

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in participants with cystic fibrosis.

Key facts

Study ID
NCT05444257
Run by
Vertex Pharmaceuticals Incorporated
People needed
822
Starts
2022-11-08
Expected to finish
2026-10-30
Last updated by the study team
2026-07-21

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.